EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Infectious bursal disease virus (IBDV) as a novel oncolytic virotherapy in glioblastoma

Vicent Tur-Planells, Yonina Bykov, Gloria Dawodu, Noemi García-Romero, Sara Izpura-Luis, Leticia Pérez-Rodríguez, Sergio Rius-Rocabert, Irina Palacín-Aliana, Javier Arranz-Herrero, Inmaculada Márquez-Leiva, Alvaro Monago-Sanchez, Maria-Luisa Del Rio und 7 weitere

Journal for ImmunoTherapy of Cancer · 2025-11 · 13 (11) · e011741

DOI: 10.1136/jitc-2025-011741 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025-11. Verfasst von Vicent Tur-Planells und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Glioblastoma, Infectious bursal disease virus, Oncolytic Viruses. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GBM) is the most aggressive form of cancer of the central nervous system. Despite advances in immunotherapies and standard-of-care treatments for GBMs, clinical outcomes remain limited—owing to the immunosuppressive tumor microenvironment and the intrinsic resistance of GBM to conventional approaches. As a result, there is growing interest in rational combination strategies, particularly those pairing oncolytic viruses with immune-based therapies or established treatment modalities. Oncolytic viruses, by displaying conditionally enabled tumor cell-restricted replication, while stimulating antitumor immune responses and leaving healthy tissue unharmed, have the potential to reshape the therapeutic landscape in GBM and aid in achieving more durable benefits for patients. This study investigates the use of infectious bursal disease virus (IBDV) as a potential virotherapy for GBM. Methods and results In vitro, IBDV infects and replicates within murine GBM cells and patient-derived GBM stem cells, inducing direct oncolysis and activating proinflammatory gene expression programs. IBDV also enhances the cytolytic activity of temozolomide (TMZ) in treated GBM cells, complementing TMZ chemotherapeutic activity. In vivo, treatment with IBDV in CT-2A GBM-bearing syngeneic mice significantly reduced tumor growth and improved survival compared with control mice. Intratumoral administration of IBDV induces a deep remodeling of the tumor immune microenvironment, reducing immunosuppressive M2-like macrophages and increasing the ratio of CD8+T cells to regulatory T cells. This reversion of immunosuppression linked to monocyte-derived macrophages has been confirmed on experimental ex vivo infections of explants derived from human GBM donors.

Conclusion

These findings support further consideration of IBDV as a novel virotherapeutic agent for GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirotherapyGlioblastomaInfectious bursal disease virusOncolytic VirusesBrain NeoplasmsAnimalsMiceHumansCell Line, TumorTumor MicroenvironmentXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Central Nervous System CancerImmunotherapyIntratumoralOncolytic virusTumor microenvironment - TME

Autor:innen und Institutionen

  • Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Microbiology Section, Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.
  • Department of Basic Medical Sciences, Facultad de Medicina, Instituto de Medicina Molecular Aplicada-Nemesio Díez (IMMA-ND), Universidad San Pablo-CEU, CEU Universities, Institute of Applied Molecular Medicine (IMMA), M…
  • Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Community of Madrid, Spain.
  • Department of Oncological Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Community of Madrid, Spain.

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Tur-Planells, V., Bykov, Y., Dawodu, G., García-Romero, N., Izpura-Luis, S., Pérez-Rodríguez, L., Rius-Rocabert, S., Palacín-Aliana, I., Arranz-Herrero, J., Márquez-Leiva, I., Monago-Sanchez, A., Del Rio, M. L., Rodriguez-Barbosa, J. I., Cano-Ochando, J., García-Sastre, A., Lozano-Ojalvo, D., Nistal-Villan, E., Ayuso-Sacido, A., & Cuadrado-Castano, S. (2025). Infectious bursal disease virus (IBDV) as a novel oncolytic virotherapy in glioblastoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-011741

Vancouver

Tur-Planells V, Bykov Y, Dawodu G, García-Romero N, Izpura-Luis S, Pérez-Rodríguez L, et al. Infectious bursal disease virus (IBDV) as a novel oncolytic virotherapy in glioblastoma. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2025-011741

BibTeX
@article{TurPlanells2025,
  author = {Tur-Planells, Vicent and Bykov, Yonina and Dawodu, Gloria and García-Romero, Noemi and Izpura-Luis, Sara and Pérez-Rodríguez, Leticia and Rius-Rocabert, Sergio and Palacín-Aliana, Irina and Arranz-Herrero, Javier and Márquez-Leiva, Inmaculada and Monago-Sanchez, Alvaro and Del Rio, Maria-Luisa and Rodriguez-Barbosa, Jose-Ignacio and Cano-Ochando, Jordi and García-Sastre, Adolfo and Lozano-Ojalvo, Daniel and Nistal-Villan, Estanislao and Ayuso-Sacido, Angel and Cuadrado-Castano, Sara},
  title = {Infectious bursal disease virus (IBDV) as a novel oncolytic virotherapy in glioblastoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2025-011741}
}
Kostenlos starten →